News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|December 13, 2024

PTSD in Society

Author(s)Arash Javanbakht, MD, Matthew Robinson, PhD, Tory Woodard, NP

Key Takeaways

A panelist discusses how posttraumatic stress disorder (PTSD) permeates modern society at multiple levels, from individuals coping with personal trauma to collective trauma responses that shape community behaviors and social structures.

Episodes in this series

4 experts are featured in this series.

EP. 1 PTSD in Society

4 experts are featured in this series.

EP. 2 PTSD Risk Factors and Changes in the Brain

4 experts are featured in this series.

EP. 3 PTSD Symptoms

4 experts are featured in this series.

EP. 4 PTSD Diagnosis and Challenges

4 experts are featured in this series.

EP. 5 Tools for PTSD Diagnosis

4 experts are featured in this series.

EP. 6 PTSD Diagnosis in Clinical Settings

4 experts are featured in this series.

EP. 7 Treatment Options for PTSD

4 experts are featured in this series.

EP. 8 Use of PTSD Treatments in Clinical Practice

4 experts are featured in this series.

EP. 9 Emerging Treatments in PTSD

4 experts are featured in this series.

EP. 10 Concluding Thoughts on PTSD Management

4 experts are featured in this series.

EP. 11 Patient Case: Trauma and Impact of PTSD on Quality of Life

PTSD

EP. 12 Panel Shares Top 7 Insights Into Addressing PTSD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

A New Option: Getting TDM Data Faster

ByJonathan M. Meyer, MD, DLFAPA

December 1st 2025

Using TDMs to Improve Care and Communication

ByJonathan M. Meyer, MD, DLFAPA

November 20th 2025

PTSD

Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD

November 17th 2025

Why Therapeutic Drug Monitoring Is Important for Antipsychotics

ByJonathan M. Meyer, MD, DLFAPA

November 13th 2025

placebo

Placebo Response Rates Vary Across Psychiatric Disorders

ByMasha Impallaria, MD,Ahmed Sakr, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 12th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Antidotes to Fear of Death

© 2025 MJH Life Sciences^®

All rights reserved.